Literature DB >> 2060627

Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease.

D Schnabel1, M Schröder, K Sandhoff.   

Abstract

The lysosomal degradation of glucosylceramide requires the hydrolase, glucosylceramide-beta-glucosidase and a sphingolipid activator protein (Gaucher factor, SAP-2, saposin C). Genetic defects in either of these lysosomal proteins cause phenotypically similar disorders in man, the Gaucher disease. SAP-2 originates from a gene which generates a mRNA that codes for four homologous proteins. In a patient with an immunologically proven SAP-2 deficiency a G1154----T transversion (counted from A of the initiation codon ATG) was found in the mRNA of the SAP-2 precursor which results in the substitution of Phe for Cys385 in the mature SAP-2. The rest of the coding sequence remained entirely normal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060627     DOI: 10.1016/0014-5793(91)80760-z

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  41 in total

1.  Analyses of temporal regulatory elements of the prosaposin gene in transgenic mice.

Authors:  Ying Sun; David P Witte; Peng Jin; Gregory A Grabowski
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

Review 2.  A short guided tour through functional and structural features of saposin-like proteins.

Authors:  Heike Bruhn
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

3.  A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD).

Authors:  D Wrobe; M Henseler; S Huettler; S I Pascual Pascual; A Chabas; K Sandhoff
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

Review 4.  The protective role of prosaposin and its receptors in the nervous system.

Authors:  Rebecca C Meyer; Michelle M Giddens; Brilee M Coleman; Randy A Hall
Journal:  Brain Res       Date:  2014-08-15       Impact factor: 3.252

5.  Sequencing of the GBA coactivator, Saposin C, in Parkinson disease.

Authors:  Bouchra Ouled Amar Bencheikh; Etienne Leveille; Jennifer A Ruskey; Dan Spiegelman; Christopher Liong; Edward A Fon; Guy A Rouleau; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Ziv Gan-Or
Journal:  Neurobiol Aging       Date:  2018-07-02       Impact factor: 4.673

6.  The exon 8-containing prosaposin gene splice variant is dispensable for mouse development, lysosomal function, and secretion.

Authors:  Tsadok Cohen; Wojtek Auerbach; Liat Ravid; Jacques Bodennec; Amos Fein; Anthony H Futerman; Alexandra L Joyner; Mia Horowitz
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  Synthesis and characterization of a bioactive 82-residue sphingolipid activator protein, saposin C.

Authors:  S Weiler; W Carson; Y Lee; D B Teplow; Y Kishimoto; J S O'Brien; J A Barranger; J M Tomich
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

Review 8.  Glycosphingolipid degradation and animal models of GM2-gangliosidoses.

Authors:  T Kolter; K Sandhoff
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

9.  Cellular uptake of saposin (SAP) precursor and lysosomal delivery by the low density lipoprotein receptor-related protein (LRP).

Authors:  T Hiesberger; S Hüttler; A Rohlmann; W Schneider; K Sandhoff; J Herz
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

10.  Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients.

Authors:  M Horowitz; G Tzuri; N Eyal; A Berebi; E H Kolodny; R O Brady; N W Barton; A Abrahamov; A Zimran
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.